Comparative Pharmacology
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus TASIGNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BOSUTINIB MONOHYDRATE versus TASIGNA.
BOSUTINIB MONOHYDRATE vs TASIGNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor. It inhibits the BCR-ABL kinase, which is constitutively active in chronic myeloid leukemia (CML), and also inhibits Src family kinases. It has minimal inhibitory activity against c-KIT and PDGFR.
Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the activity of BCR-ABL, the constitutively activated fusion protein responsible for chronic myeloid leukemia (CML). It also inhibits other kinases including KIT, PDGFR, and DDR1.
400 mg orally once daily with food.
400 mg orally twice daily approximately every 12 hours. Administer on an empty stomach (no food for at least 2 hours before and 1 hour after dose). Swallow whole with water; do not crush or chew.
None Documented
None Documented
22.5 hours; supports once-daily dosing, with steady-state achieved by day 8.
Terminal elimination half-life is approximately 90-120 hours, supporting once-daily dosing.
Primarily fecal (91%, as unchanged drug and metabolites) with renal excretion accounting for <3%.
Primarily fecal (approximately 66-93% of the dose) as unchanged drug and metabolites; renal excretion is minimal (<5% of the dose).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor